// consumer behavior

Source: The Prof G Pod

The longevity market—anchored by GLP-1 drugs, peptides, and emerging biotech—is creating a durably stratified health economy where wealthy early adopters get years of competitive advantage in healthspan while the broader population waits for regulatory approval, insurance coverage, and price normalization that may never fully arrive. This is a structural feature, not a temporary access gap: the most expensive interventions (continuous monitoring, bespoke peptide protocols, preventive biomarkers) will remain concentrated among those who can pay direct-to-consumer, while mass-market versions, if they materialize, arrive 5-10 years later and often in inferior form. The real business consolidation happening now is not pharma's but among concierge clinics, direct-to-consumer platforms, and wealth management advisors who are packaging longevity as a luxury service and widening the gap between premium and standard medicine.

Source: The Register

Microsoft has weaponized the out-of-box experience—traditionally a neutral onboarding moment—into a sales funnel that routes users directly to subscription offers before IT departments can enforce purchasing policies. The setup screens capture end-user buying decisions that would normally route through corporate procurement, effectively disintermedating the IT buyer and converting approval processes into direct-to-consumer revenue. The move exposes how consumer-grade operating systems have become dual-use sales platforms. Microsoft views Windows primarily as a distribution asset for its subscription stack rather than as infrastructure IT should control.